A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma
DNA aptamers represent a novel strategy in anti-cancer medicine.01/22/2014
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology